Hepatitis C virus (HCV) RNA decay during antiviral therapy is characterized by a rapid first phase, followed by a slower second phase. The current understanding of viral kinetics attributes the magnitude of the first phase of decay to treatment effectiveness, whereas the second phase of decay is att
Telaprevir-based treatment effects on hepatitis C virus in liver and blood
β Scribed by Talal, Andrew H.; Dimova, Rositsa B.; Zhang, Eileen Z.; Jiang, Min; Penney, Marina S.; Sullivan, James C.; Botfield, Martyn C.; Chakilam, Ananthsrinivas; Sawant, Rishikesh; Cervini, Christine M.; Zeremski, Marija; Jacobson, Ira M.; Kwong, Ann D.
- Book ID
- 126906609
- Publisher
- John Wiley and Sons
- Year
- 2014
- Tongue
- English
- Weight
- 1012 KB
- Volume
- 60
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The effect of hepatitis C virus (HCV) and its treatment on survival is not well defined. We undertook this study to determine the effect of HCV and its treatment on survival in a national cohort of HCV-infected veterans and uninfected controls. We used a national sample of HCV-infected persons and H
Since the natural history of hepatitis C virusassociated liver disease and the therapeutic responsiveness might vary according to liver and blood mononuclear cells viral levels, it may be important to quantitate viral RNA in liver, blood mononuclear cells and serum, and to compare these data with ge